GeneSystem Co

GeneSystem Co Debt/EBITDA

The Total Debt to EBITDA Ratio of GeneSystem Co (363250.KQ) as of Nov 4, 2026 is -0.20. In the previous year, Total Debt to EBITDA Ratio was -0.35 — a change of -41.95% (higher).

Debt/EBITDA

-0.20

YoY

-41.95%

Last updated:

Total Debt to EBITDA Ratio of GeneSystem Co is 2025 -0.20 . Total Debt to EBITDA Ratio of GeneSystem Co was 2024 -0.35 . It decreases by -41.95% higher compared to the previous year.

The GeneSystem Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-2.19 KRW
Jan 1, 2019
-0.98 KRW
Jan 1, 2020
1.12 KRW
Jan 1, 2021
1.61 KRW
Jan 1, 2022
-0.62 KRW
Jan 1, 2023
-0.44 KRW
Jan 1, 2024
-0.35 KRW
Jan 1, 2025
-0.20 KRW
The GeneSystem Co Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.20-41.95%
-0.35-20.71%
-0.44-29.75%
-0.62-138.62%
1.61+43.85%
1.12-214.36%
-0.98-55.47%
-2.19—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Total Debt to EBITDA Ratio of GeneSystem Co is -0.20 in 2025.

Total Debt to EBITDA Ratio of GeneSystem Co changed from -0.35 to -0.20, representing a -41.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GeneSystem Co

All Key Metrics — GeneSystem Co